Articles

O.5 Sequential administration of 5-azacytidine (AZA) and donor lymphocyte infusion (DLI) for patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) in relapse after allogeneic stem cell transplantation (SCT): an interim analysis from the Belgian Hematology Society (BHS)

BJH - volume 8, issue Abstract Book BHS, february 2017

X. Poiré MD, PhD, C. Graux MD, PhD, A. Ory , J. Jamart , F. Frédéric , H. Schoemans MD, PhD, P. Lewalle MD, PhD, A. De Becker MD, D. Deeren , Z. Berneman MD, PhD, T. Kerre MD, PhD, P. Zachée MD, PhD, D. Selleslag MD, Y. Beguin MD, PhD

Read more

Highlights on Myelodysplastic Syndromes (MDS)

BJH - volume 8, issue 1, february 2017

D. Selleslag MD

SUMMARY

This ASH 2016 report will focus on the diagnostic and prognostic utility of molecular abnormalities and on new treatment modalities in MDS. We selected 7 abstracts dealing with these topics.

(BELG J HEMATOL 2017;8(1):34–7)

Read more

O.1 Infusion of mesenchymal stem cells (MSC) as treatment for steroid refractory acute graft-versus-host study (aGVHD): a multicenter prospective phase II study of the BHS

BJH - volume 7, issue Abstract Book BHS, january 2016

S. Servais MD, PhD, D. Selleslag MD, J. Maertens MD, PhD, L. Lechanteur , E. Baudoux MD, P. Zachée MD, PhD, H. Schouten , L. Noens MD, PhD, P. Lewalle MD, PhD, W. Schroyens MD, PhD, A. Ory , Y. Beguin MD, PhD

Read more

P4.06 Cost minimization analysis of a home administration program in Belgium

BJH - volume 7, issue Abstract Book BHS, january 2016

D. Selleslag MD, S. De Ruysscher , J. Patris , S. Vermeersch , J. Verstraete , P. Persyn , K. Herman , H. van Loon , L. Annemans

Read more

P4.10 The Ponatinib Named Patient Programme (NPP): Real-life Data from Belgian Patients

BJH - volume 7, issue Abstract Book BHS, january 2016

L. Knoops MD, PhD, G. Verhoef MD, PhD, Z. Berneman MD, PhD, D. Selleslag MD, N. Straetmans MD, PhD, L. Noens MD, PhD, P. Lewalle MD, PhD, M. André MD, PhD, D. Pranger MD, P. Zachée MD, PhD, E. Strobbe , L.J. McGarry , T. Devos MD, PhD

Read more

BHS 2013 recommendations for treatment of myelodysplastic syndromes

BJH - volume 6, issue 2, may 2015

S. Meers MD, PhD, D. Breems MD, PhD, G. Bries MD, PhD, M. Delforge MD, PhD, C. Graux MD, PhD, D. Selleslag MD, L. Noens MD, PhD

Summary

The guidelines on the current state-of-the-art in the diagnosis and treatment of myelodysplastic syndromes of the Belgian Hematological Society working group on myelodysplastic syndromes were published in 2013.1 The key points of these guidelines are presented in two issues of the Belgian Journal of Hematology. In this paper we present the optimal treatment of patients with myelodysplastic syndromes within the current limitations of Belgian reimbursement modalities.

(BELG J HEMATOL 2015;6(2):54–60)

Read more

The 2013 Belgian Hematological Society recommendations for the diagnosis and classification of myelodysplastic syndromes

BJH - volume 6, issue 1, march 2015

S. Meers MD, PhD, D. Breems MD, PhD, G. Bries MD, PhD, M. Delforge MD, PhD, C. Graux MD, PhD, D. Selleslag MD, L. Noens MD, PhD

Summary

The Belgian Hematological Society working group on myelodysplastic syndromes published their guidelines on the state of the art in diagnosis and treatment of myelodysplastic syndromes and the key points of these recommendations are presented in two issues of the Belgian Journal of Hematology.1 In this first paper we present the requirements for a correct diagnosis and classification of patients with myelodysplasia.

(BELG J HEMATOL 2015;6(1):10–5)

Read more